NEWS
2024-06-18 08:30
LIPUM REPORTS FURTHER PROGRESS WHERE THE MULTIPLE DOSE PART OF THE PHASE I CLINICAL STUDY IS COMPLETED
Lipum AB (publ) announces that the multiple dose part of the phase I clinical study is completed. Eight healthy subjects have received four doses 28 days...
2024-05-28 08:00
Lipum AB – interim report Q1 for the period January-March 2024
Lipum AB (publ) has published the interim report Q1 for the period January-March 2024. Below is a summary, a complete report (only in Swedish) is available...
2024-05-06 09:00
Lipum receives loan commitment of SEK 20 million
Lipum AB (publ) has signed an agreement with Flerie Invest AB including a loan commitment of SEK 20 million. The agreement which has been signed on market...
2024-04-25 13:10
Lipum announces final outcome of the rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
2024-04-23 18:40
Lipum announces preliminary outcome of the rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
Lipum AB (Publ), a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases...
2024-04-12 16:00
Lipum has been granted funding from Swelife
Lipum (publ) announce today that the project “Identifying proteomic biomarkers to predict the course of early RA” has been granted 2,8 MSEK...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
2024-04-03 12:45
Lipum publishes prospectus regarding the rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
2024-04-02 13:25
Lipum AB - Report from the Extraordinary General Meeting
An Extraordinay General Meeting (the “EGM”) in Lipum AB (publ), corporate identity number 556813-5999 (“Lipum” or the “Company”)...